Search results for "biopharma"
Article
Managing Biomanufacturing Capacity Expectations
According to a new survey by BioPlan Associates, more than half of respondents (60%) expect facility constraints to create biopharmaceutical production capacity constraints by 2021 (1). BioPlan found …
Article
Biomanufacturing Outsourcing Globalization Continues
Langer
BioPharm International
Volume 28, Issue 5
Biopharmaceutical manufacturing clusters continue to emerge outside of the traditional hubs of North America and Western Europe. Contract m…
Article
Cell-Culture Advances Test Bioreactor Performance Models
In particular, the inexpensive computing power and excellent computational talent entering the biopharma industry, combined with improvements in computational fluid dynamics (CFD) and metabolic modeli…
Article
Tools and Processes for Mature and Emerging Therapies
Cytiva also announced a partnership with Rockwell Automation to use augmented reality technology; biopharma companies will be able to monitor production processes, review equipment setup, provide inst…
Article
Biomanufacturing: The Cost of Unskilled Workers
First, a 2018 report from BioPlan Associates estimates there are well over 10,000 therapeutics in R&D, both drugs (chemical substance pharmaceuticals) and biopharmaceuticals (biotechnology-derived pha…
Article
Transformative Medicines Challenge FDA and Manufacturers
Biopharma researchers also are achieving success in developing oligonucleotide therapies, including antisense drugs and short interfering RNA treatments (siRNAs) that can modulate immune pathways. Saf…
Article
Q&A with Eric Langer, about the evolution of the role of CMO’s in Bioprocessing
PDF: Contract Manufacturing Organizations (CMO’s) seem to be assuming a larger role in biopharma processing. Can you tell us why that is?
Eric: Based on our 11th Annual Report, this focus on pro…
Article
Q&As with Industry Leaders
…er, PhD, Senior Scientist, Bioprocess Applications R&D, Cytiva
Lessons Learned from the Biopharma Industry's Response to the COVID-19 Pandemic
James Blackwell, President, Windshire Group,…
Article
Moving Biosimilars Forward in a Hesitant Market
On the pricing pressure aspect in the biopharma market, Gabrielson asserts that pricing pressure is a central theme in biosimilars. “That is why these products exist, fundamentally,” he remarks, “to m…
Article
Bracing for a Future Wave of Advanced Therapies
Buoyed by the regulatory approval of several cell and gene therapy (CGT) products for difficult-to-treat diseases, the US biopharma industry is now bracing for a new wave of CGTs in the near future as…